NCT05714748 is a Phase 1 clinical trial of EBV mRNA vaccine in Malignant Tumors, sponsored by West China Hospital.

Who is sponsoring NCT05714748?

NCT05714748 is sponsored by West China Hospital.

What drugs are being tested in NCT05714748?

Interventions in NCT05714748: EBV mRNA vaccine.

What condition does NCT05714748 study?

NCT05714748 studies Malignant Tumors.

Is NCT05714748 still recruiting?

NCT05714748 is currently active, enrolled. Last updated 4 June 2025.

Last reviewed 2025-06-04 · How we verify

NCT05714748

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant Tumors

Active, enrolled Phase 1 Last updated 4 June 2025

What this trial tests

Phase 1 trial testing EBV mRNA vaccine in Malignant Tumors in 19 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

8 February 2023

Primary endpoint
31 May 2025

31 May 2025

Quick facts

Lead sponsor	West China Hospital
Phase	Phase 1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	19
Start date	8 February 2023
Primary completion	31 May 2025
Estimated completion	31 May 2025
Sites	1 location across China

Drugs / interventions tested

EBV mRNA vaccine — full drug profile →

Conditions studied

Malignant Tumors — all drugs for Malignant Tumors →

Sponsor

West China Hospital

Who can join

Adults 18 to 70, any sex, with Malignant Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the efficacy and safety of mRNA vaccine for the EBV-positive Advanced Malignant Tumors.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities.
Wang B, Pei J, Xu S, Liu J, et al · · 2023 · cited 72× · PMID 37744371 · DOI 10.3389/fimmu.2023.1246682
Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications.
Shi Y, Shi M, Wang Y, You J. · · 2024 · cited 67× · PMID 39543114 · DOI 10.1038/s41392-024-02002-z
Recent developments in immunotherapy for gastrointestinal tract cancers.
Chong X, Madeti Y, Cai J, Li W, et al · · 2024 · cited 52× · PMID 39123202 · DOI 10.1186/s13045-024-01578-x
Viral oncogenesis in cancer: from mechanisms to therapeutics.
Xiao Q, Liu Y, Li T, Wang C, et al · · 2025 · cited 45× · PMID 40350456 · DOI 10.1038/s41392-025-02197-9
Advances in mRNA-Based Cancer Vaccines.
Ni L. · · 2023 · cited 33× · PMID 37897001 · DOI 10.3390/vaccines11101599
Clinical development of therapeutic mRNA applications.
Żak MM, Zangi L. · · 2025 · cited 28× · PMID 40143545 · DOI 10.1016/j.ymthe.2025.03.034
How I treat posttransplant lymphoproliferative disorder.
Amengual JE, Pro B. · · 2023 · cited 27× · PMID 37540819 · DOI 10.1182/blood.2023020075
Enabling mRNA Therapeutics: Current Landscape and Challenges in Manufacturing.
Youssef M, Hitti C, Puppin Chaves Fulber J, Kamen AA. · · 2023 · cited 25× · PMID 37892179 · DOI 10.3390/biom13101497

Verify or expand the search:

Other trials of EBV mRNA vaccine

Trials testing the same drug.

NCT07101536 — The Application of mRNA Immunotherapy Technology in Refractory Malignancies Associated With Epstein-Barr Virus (EBV) · NA · not yet recruiting

Other recruiting trials for Malignant Tumors

Currently open trials in the same condition.

NCT07112222 — A Study of LM-350 in Subjects With Advanced Solid Tumours · Phase 1, PHASE2 · recruiting
NCT07301801 — Clinical Application of 68Ga-FL-031 PET in the Diagnosis and Staging of Malignant Tumors · EARLY_PHASE1 · recruiting
NCT07004244 — Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies · Phase 1 · recruiting
NCT06944444 — A Phase I Clinical Study of SSS59 Monotherapy in Patients With Advanced Malignant Tumors · Phase 1 · recruiting
NCT05615974 — A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors · Phase 1, PHASE2 · recruiting

Other West China Hospital trials

Trials by the same sponsor.

NCT07583654 — Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors · Phase 1 · not yet recruiting
NCT07583914 — Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors · Phase 1 · not yet recruiting
NCT07492914 — Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma · Phase 2 · recruiting
NCT07507097 — Study on the Optimal Head Position for Patients With Severe Acute Ischemic Stroke · NA · not yet recruiting
NCT07472933 — Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05714748 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by West China Hospital
Last refreshed: 4 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05714748.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing